Literature DB >> 26010271

Temozolomide induced bone marrow Suppression--A single institution outcome analysis and review of the literature.

Taxiarchis V Kourelis1, Jan C Buckner2, Naseema Gangat1, Mrinal M Patnaik1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26010271     DOI： 10.1002/ajh.24066

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

1.  Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma.

Authors:  Miguel Jiménez-Alcázar; Álvaro Curiel-García; Paula Nogales; Javier Perales-Patón; Alberto J Schuhmacher; Marcos Galán-Ganga; Lucía Zhu; Scott W Lowe; Fátima Al-Shahrour; Massimo Squatrito
Journal:  Mol Cancer Ther       Date:  2021-04-12       Impact factor: 6.009

2.  Temozolomide-induced Aplastic Anemia Treated with Eltrombopag and Granulocyte Colony Stimulating Factor: A Report of a Rare Complication.

Authors:  Shauna L Newton; Kadra Kalamaha; Hermina D Fernandes
Journal:  Cureus       Date:  2018-09-18

3.  Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study.

Authors:  Amir Massarweh; Roi Tschernichovsky; Amos Stemmer; Alexandra Benouaich-Amiel; Tali Siegal; Noa Eliakim-Raz; Salomon M Stemmer; Shlomit Yust-Katz
Journal:  J Neurooncol       Date:  2022-01-12       Impact factor: 4.506

4.  Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma.

Authors:  Hyunkoo Kang; Sungmin Lee; Kyeongmin Kim; Jaewan Jeon; Seok-Gu Kang; HyeSook Youn; Hae Yu Kim; BuHyun Youn
Journal:  J Exp Clin Cancer Res       Date:  2021-09-06

5.  PDCD10 promotes the aggressive behaviors of pituitary adenomas by up-regulating CXCR2 and activating downstream AKT/ERK signaling.

Authors:  Jingdian Liu; Junwen Wang; Weidong Tian; Yu Xu; Ran Li; Kai Zhao; Chao You; Yuan Zhu; Joerg Walter Bartsch; Hongquan Niu; Huaqiu Zhang; Kai Shu; Ting Lei
Journal:  Aging (Albany NY)       Date:  2022-08-11       Impact factor: 5.955

6.  Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.

Authors:  Antje Wick; Annick Desjardins; Cristina Suarez; Peter Forsyth; Ivelina Gueorguieva; Tiana Burkholder; Ann Louise Cleverly; Shawn T Estrem; Shuaicheng Wang; Michael M Lahn; Susan C Guba; David Capper; Jordi Rodon
Journal:  Invest New Drugs       Date:  2020-03-05       Impact factor: 3.850
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.